February 28, 2017
Dodick & Associates completes the sale of the assets of Web Offset Publications Limited (“Web”), a printer of trade publications, to Renaissance Printing Inc., a company jointly owned by Annex Publishing & Printing Inc. (“Annex”) and Reliable Bookbinders Ltd. Annex is Canada’s largest privately held media company. The sale will result in the continued operation of Web’s 200,000 sqf printing facility, maintain 90 manufacturing jobs, and create new investment, in Pickering, Ontario.
November 29, 2016
Dodick & Associates completes the sale of the assets of Newstart Financial Inc. and Newstart Acceptance Inc., which provided automobile, and micro loan, financing to over 670 customers in the subprime market, to 9467971 Canada Inc. (“946”), a newly incorporated company owned by a group of private individuals. The sale will result in the continued financing by 946 of subprime borrowers.
March 27, 2015
Dodick & Associates completes the sale of the assets of True North Hardwood Plywood Inc. (“True North”) to Rockshield Engineered Wood Products ULC (“Rockshield”), a wholly owned subsidiary of Rockshield Capital Corp. (CSE: RKS). The sale will result in the re-start of True North’s 150,000 sqf hardwood plywood manufacturing facility, create over 100 new manufacturing jobs, and invest millions of dollars, in Cochrane, Ontario and the surrounding communities. Rockshield will commence plywood production in April 2015 and will distribute its plywood products to markets in Canada and the United States. Rockshield’s plywood products will be used in furniture and cabinetry, commercial millwork, wall paneling, stair parts, manufactured housing, and doors.
November 21, 2014
Dodick & Associates completes the sale of all the assets of Mitomics Inc. (“Mitomics”) to MDNA Life Sciences Inc. (“MDNA”). Mitomics is a molecular diagnostic company engaged in research, development and implementation of medical tests and devices for the early detection of cancers. Mitomics has numerous patent registrations and patents pending in Canada, the United States, and in other jurisdictions, as well as various other trade secrets, know-how and intellectual property rights. The sale will result in MDNA continuing to make investments in the research and development of medical tests and devices for the early detection of cancers.